These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 17920755

  • 1. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.
    Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR.
    Exp Hematol; 2007 Nov; 35(11):1641-6. PubMed ID: 17920755
    [Abstract] [Full Text] [Related]

  • 2. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
    Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR.
    N Engl J Med; 2007 Feb 01; 356(5):459-68. PubMed ID: 17267906
    [Abstract] [Full Text] [Related]

  • 3. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Feb 01; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 4. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
    Siemiatkowska A, Bieniaszewska M, Hellmann A, Limon J.
    Leuk Res; 2010 Mar 01; 34(3):387-9. PubMed ID: 19643476
    [Abstract] [Full Text] [Related]

  • 5. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
    Maddali M, Kulkarni UP, Ravindra N, Jajodia E, Arunachalam AK, Suresh H, Venkatraman A, George B, Mathews V, Balasubramanian P.
    Ann Hematol; 2020 May 01; 99(5):983-989. PubMed ID: 32277273
    [Abstract] [Full Text] [Related]

  • 6. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
    Rabade N, Subramanian PG, Kodgule R, Raval G, Joshi S, Chaudhary S, Mascarenhas R, Tembhare P, Gujral S, Patkar N.
    Indian J Pathol Microbiol; 2018 May 01; 61(2):209-213. PubMed ID: 29676359
    [Abstract] [Full Text] [Related]

  • 7. JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
    Giraldo-Rincón AI, Naranjo Molina S, Gomez-Lopera N, Aguirre Acevedo D, Ucroz Benavidez A, Gálvez Cárdenas K, Cuellar Ambrosí F, Torres JD, Ospina S, Palacio K, Gaviria Jaramillo L, Muñeton CM, Vasquez Palacio G.
    Colomb Med (Cali); 2023 May 01; 54(3):e2035353. PubMed ID: 38111518
    [Abstract] [Full Text] [Related]

  • 8. MPL W515L mutation in Chinese patients with myeloproliferative diseases.
    Xu W, Li JY, Xia J, Zhang SJ, Fan L, Qiao C.
    Leuk Lymphoma; 2008 May 01; 49(5):955-8. PubMed ID: 18464114
    [Abstract] [Full Text] [Related]

  • 9. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
    Poluben LO, Neumerzhytska LV, Klymenko SV, Fraenkel P, Balk C, Shumeiko OO.
    Probl Radiac Med Radiobiol; 2020 Dec 01; 25():362-373. PubMed ID: 33361847
    [Abstract] [Full Text] [Related]

  • 10. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.
    Moliterno AR, Williams DM, Rogers O, Spivak JL.
    Blood; 2006 Dec 01; 108(12):3913-5. PubMed ID: 16912229
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
    Martínez-Avilés L, Besses C, Alvarez-Larrán A, Cervantes F, Hernández-Boluda JC, Bellosillo B.
    Haematologica; 2007 Dec 01; 92(12):1717-8. PubMed ID: 18056003
    [Abstract] [Full Text] [Related]

  • 13. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
    Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL.
    Exp Hematol; 2008 Nov 01; 36(11):1480-6. PubMed ID: 18723264
    [Abstract] [Full Text] [Related]

  • 14. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS.
    Am J Clin Pathol; 2015 May 01; 143(5):635-44. PubMed ID: 25873496
    [Abstract] [Full Text] [Related]

  • 15. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2017 Jan 01; 92(1):94-108. PubMed ID: 27991718
    [Abstract] [Full Text] [Related]

  • 16. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr 01; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Labastida-Mercado N, Galindo-Becerra S, Garcés-Eisele J, Colunga-Pedraza P, Guzman-Olvera V, Reyes-Nuñez V, Ruiz-Delgado GJ, Ruiz-Argüelles GJ.
    Hematol Oncol Stem Cell Ther; 2015 Mar 01; 8(1):16-21. PubMed ID: 25637689
    [Abstract] [Full Text] [Related]

  • 19. Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden.
    Nussenzveig RH, Pham HT, Perkins SL, Prchal JT, Agarwal AM, Salama ME.
    Leuk Lymphoma; 2016 Mar 01; 57(6):1429-35. PubMed ID: 26419289
    [Abstract] [Full Text] [Related]

  • 20. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
    Lyu XD, Li YW, Guo Z, Xin YP, Hu JY, Fan RH, Song YP.
    Zhonghua Nei Ke Za Zhi; 2020 Jan 01; 59(1):35-39. PubMed ID: 31887834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.